Delivery Order SPE2DB20D3101-SPE2DB25FRQT9
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 5, 2025. This non-competitive, firm fixed-price delivery order was issued on August 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used for cholesterol management in patients with cardiovascular...
- The Defense Logistics Agency (DLA) awarded a $24,925.53 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors on September 18, 2025, with an ultimate completion date of September 19, 2025. This firm fixed-price, competitively awarded contract was placed with no set-aside designation and is being performed at the contractor's facility in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol, and the SureClick...
- The Defense Logistics Agency awarded a $20,623.85 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of July 22, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $7,444.93 for REPATHA 140 mg/ml SureClick auto-injector pens on September 11, 2025, with ultimate completion by September 12, 2025. This firm fixed price, non-set-aside delivery order will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol and reduce cardiovascular risk, typically administered via pre-filled...
- The Defense Logistics Agency awarded a delivery order valued at $1,769.15 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 6, 2025. This is a firm fixed-price, non-set-aside contract issued on August 5, 2025, with performance at the vendor's Conshohocken, Pennsylvania headquarters. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol and reduce cardiovascular risk in patients with established heart...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors valued at $1,135.11, with completion scheduled for September 9, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX. The product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $4,115.11 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors on September 2, 2025, with completion scheduled for September 3, 2025. This firm fixed-price delivery order represents a non-competitive procurement and is being fulfilled by AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. REPATHA is a prescription medication used to lower cholesterol levels and reduce cardiovascular...
- The Defense Logistics Agency (DLA) awarded a delivery order contract valued at $1,214.99 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of August 5, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. REPATHA is a prescription medication used to lower cholesterol levels and...
- The Defense Logistics Agency awarded a $53,478.59 firm fixed price delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors on September 2, 2025, with an ultimate completion date of September 3, 2025. This non-set-aside competitive award is being performed at the company's corporate office in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a monoclonal antibody used to treat high cholesterol in patients with cardiovascular disease, and the SureClick...
- The Defense Logistics Agency awarded a delivery order valued at $7,425.26 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 19, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 and extending through December 2026. The...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRQT9Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,388.56 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of July 23, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used for cholesterol management, and the SureClick auto-injector delivery mechanism provides convenient self-administration for patients requiring this specialty pharmaceutical. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a prime vendor for the Defense Logistics Agency's Medical Supply Chain, AmerisourceBergen supplies pharmaceutical products and medical commodities to support military healthcare systems and the Defense Health Agency. The company's extensive federal contract portfolio demonstrates its established capability to meet competitive procurement requirements across a comprehensive range of therapeutic domains, from specialty medications to vaccines and medical devices, supporting military personnel and veterans globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 7/22/25 |